Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.35 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.35 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4220081 | 0.80 | ABCB1 (0.38) | HTR2CHTR2BPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL4225917 | 0.79 | GPR52 (0.42) | GPR52TP53ATMTSHRALDH1A1 | |
| SCHEMBL4228680 | 0.79 | PRKAB2 (0.39) | GPR52PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL5791592 | 0.78 | PRKAB2 (0.54) | HTR2CHTR2BGPR52PRKAB2PRKAG1 | |
| SCHEMBL4225706 | 0.78 | PRKAB2 (0.54) | HTR2CHTR2BGPR52PRKAB2PRKAG1 | |
| SCHEMBL4223650 | 0.77 | PRKAB2 (0.37) | HTR2CHTR2BPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL4963564 | 0.76 | HTR2C (0.38) | HTR2CHTR2BPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL6104848 | 0.76 | HTR2C (0.38) | HTR2CHTR2BPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL4225092 | 0.76 | OXTR (0.48) | GPR52ATMALDH1A1HTT | |
| SCHEMBL4222323 | 0.74 | LMNA (0.37) | CYP3A4CYP2D6CYP2C19TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007509174-A | — | — | 2007-04-12 | — | — | JP | claimed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | claimed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | claimed |
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007030150-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH (US) | 2007-03-15 | — | — | WO | disclosed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | HTR2C, HTR1A, HTR3A | HTR2C 1/4885HTR2B 6/4885GPR52 67/4885 |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | HTR2C 1/4885HTR2B 6/4885GPR52 67/4885 |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | HTR2C 6/4885HTR2B 11/4885GPR52 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.